High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

NCT07700030 · Not yet recruiting

Last updated 2026-07-28

This clinical trial tests whether a high-protein diet combined with resistance training helps maintain muscle mass in people using GLP-1 receptor agonist medications for weight loss.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) prevention study

Participants 32 people Planned (estimated).

Who can join Ages 30–60 · all sexes

Timeline Started 2026-07 · est. completion 2027-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07700030 ↗

Description as written by the study sponsor.

The primary objective of this study is to examine the effects of a high-protein diet (HP) paired with resistance training (RT) compared with a HP diet alone, on skeletal muscle mass (SMM) volume of the (a) quadriceps and (b) rhomboids, and upper and lower body muscle strength in adults recently prescribed tirzepatide. The secondary objectives of this study are to compare changes in resting energy expenditure (REE), adaptive thermogenesis (AT), and body adiposity (SFV, VAT, and intramuscular FF) in the quadriceps and rhomboid muscles) between the high-protein diet with RT and the high-protein diet arms at 6 months.

Treatments tested

High protein diet Other

The standardized highprotein diet counseling focuses on achieving 2.5 g/kg FFM/day of dietary protein through food and commercially available protein powder supplements that will be provided to participants.
Resistance Training (RT) Programs Behavioral

Supervised RT program designed for muscle hypertrophy (2 sessions/week, \~45-60 minutes each)

Main thing measured	Changes in lean Skeletal Muscle Mass (SMM) quadriceps
Sponsor	NYU Langone Health
Conditions studied	Weight Loss
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07700030 ↗